InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures $5.75M in Underwritten Public Offering
September 30, 2022

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures $5.75M in Underwritten Public Offering

Silo Pharma (NASDAQ: SILO) (formerly OTCQB: SILO) is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company today announced the closing of its underwritten public offering of 1,150,000 shares of its common stock, which included the full exercise of the underwriters’ over-allotment option to purchase 150,000 additional shares of common stock, each at a public offering price of $5.00. Silo Pharma’s common stock began trading on the Nasdaq Capital Market on Sept. 27, 2022, under the symbol SILO. The company secured $5,750,000 million in gross proceeds from the offering, before deducting underwriting discounts and commissions and other expenses. Silo Pharma intends to use the net proceeds for product development, marketing, working capital and general corporate purposes. In addition, a portion of the proceeds may be used for acquisitions of complementary businesses, technologies or other assets. Laidlaw & Company (U.K.) Ltd. acted as sole book-running manager for the offering.

To view the full press release, visit https://ibn.fm/nFGPA

About Silo Pharma Inc.

Silo Pharma is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which it believes will be transformative to the well-being of patients and the health care industry. For more information about the company, visit www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).